|
|||||||||
|
|||||||||
 | |||||||||
 | |||||||||
|
CME News A review of data from RCTs and observational studies found low MI risk with either coxibs or NSAIDs (highest with rofecoxib), and significantly fewer serious upper GI events with coxibs... Orthopaedic News Acupuncture should be considered an option for postop pain control among patients after orthopaedic surgery... Horizon Therapeutics, Inc, a privately-held, late-stage biopharmaceutical company, has initiated a phase III follow-on safety study (HZ-CA-304) of its lead product candidate HZT-501, an investigational prescription NSAID (nonsteroidal anti-inflammatory drug) designed to be "GI-friendly"... |
|
 |
|
 Rheumatology and Infusion Therapy: Practice and Treatment Choices in the New Era | |
 The Scientific Basis of Individualized Treatment of Patients With RA: Online Byte-Size CME | |
To remove your e-mail address from our mailing list, please send a blank email to unsubscribe@fbhc.org. For questions and comments regarding this newsletter please contact info@ciaomed.org | |
